paroxetine sold brand names paxil seroxat among others antidepressant selective serotonin reuptake inhibitor ssri used treat major depressive disorder obsessivecompulsive disorder panic disorder social anxiety disorder posttraumatic stress disorder generalized anxiety disorder premenstrual dysphoric also used treatment premature ejaculation hot flashes due taken orally common side effects include drowsiness dry mouth loss appetite sweating trouble sleeping sexual serious side effects may include suicidal thoughts age serotonin syndrome rate side effects appears similar compared ssris snris antidepressant discontinuation syndromes may occur use pregnancy recommended use breastfeeding relatively believed work blocking reuptake chemical serotonin neurons paroxetine approved medical use united states initially sold world health organizations list essential available generic commonly prescribed medication united states million top prescribed antidepressants united united states department justice fined glaxosmithkline billion withholding data unlawfully promoting use preparing article misleadingly reported effects paroxetine adolescents depression following clinical trial study paroxetine primarily used treat major depressive disorder obsessivecompulsive disorder posttraumatic stress disorder social anxiety disorder panic disorder also occasionally used agoraphobia generalized anxiety disorder premenstrual dysphoric disorder menopausal hot variety metaanalyses conducted evaluate efficacy paroxetine depression variously concluded paroxetine superior equivalent placebo equivalent despite clear evidence paroxetine better worse compared antidepressants increasing response treatment point paroxetine first antidepressant approved united states treatment panic needed several studies concluded paroxetine superior placebo treatment panic paroxetine demonstrated efficacy treatment social anxiety disorder adults also beneficial people cooccurring social anxiety disorder alcohol use appears similar number paroxetine used treatment obsessivecompulsive comparative efficacy paroxetine equivalent clomipramine paroxetine also effective children obsessivecompulsive paroxetine approved treatment ptsd united states japan united states approved shortterm paroxetine also fdaapproved generalized anxiety lowdose paroxetine approved us treatment moderatetosevere vasomotor symptoms hot flashes night sweats associated low dose used menopausal hot flashes side effects similar placebo dose tapering required studies also shown paroxetine appears welltolerated improve overall symptomatology patients fibromyalgia less robust helping pain common side effects include drowsiness dry mouth loss appetite sweating insomnia sexual serious side effects may include suicide age serotonin syndrome rate side effects appears similar compared ssris snris antidepressant discontinuation syndromes may occur use pregnancy recommended use breastfeeding relatively paroxetine shares many common adverse effects ssris including corresponding rates seen people treated placebo parentheses adverse effects transient go away continued treatment central peripheral receptor stimulation believed result gastrointestinal effects observed ssri compared ssris lower incidence diarrhea higher incidence anticholinergic effects eg dry mouth constipation blurred vision etc sedationsomnolencedrowsiness sexual side effects weight due reports adverse withdrawal reactions upon terminating treatment committee medicinal products human use european medicines agency recommends gradually reducing several weeks months decision withdraw see also discontinuation syndrome withdrawal mania hypomania may occur patients depression patients bipolar side effect occur individuals history mania may likely occur bipolar disorder family history like antidepressants paroxetine may increase risk suicidal thinking behaviour people age fda conducted statistical analysis paroxetine clinical trials children adolescents found increase suicidality ideation compared placebo observed trials depression anxiety paper published bmj reanalysed original case notes argued study assessing paroxetine imipramine placebo adolescents depression incidence suicidal behavior underreported efficacy exaggerated sexual dysfunction including loss libido anorgasmia lack vaginal lubrication erectile dysfunction one commonly encountered adverse effects treatment paroxetine ssris early clinical trials suggested relatively low rate sexual dysfunction recent studies investigator actively inquires sexual problems suggest incidence higher symptoms sexual dysfunction reported persist discontinuing ssris although thought antidepressant exposure including paroxetine associated shorter duration pregnancy three days increased risk preterm delivery lower birth weight g oz lower apgar scores american college obstetricians gynecologists recommends pregnant women women planning become pregnant paroxetine avoided possible may associated increased risk birth babies born women used paroxetine first trimester increased risk cardiovascular malformations primarily ventricular atrial septal defects unless benefits paroxetine justify continuing treatment consideration given stopping switching another paroxetine use pregnancy associated increase congenital birth defects particular heart defects cleft lip palate clubbed feet birth many psychoactive medications cause withdrawal symptoms upon discontinuation administration paroxetine among highest incidence rates severity withdrawal syndrome medication common withdrawal symptoms paroxetine include nausea dizziness lightheadedness vertigo insomnia nightmares vivid dreams feelings electricity body well rebound depression anxiety liquid formulation paroxetine available allows gradual decrease dose may prevent discontinuation syndrome another recommendation temporarily switch fluoxetine longer halflife thus decreases severity discontinuation us fda published warning regarding severe discontinuation symptoms among terminating paroxetine treatment including paraesthesia nightmares dizziness agency also warned case reports describing agitation sweating nausea connection glaxo spokespersons statement withdrawal reactions occur patients mild shortlived international federation pharmaceutical manufacturers associations said gsk breached two federations codes paroxetine prescribing information posted glaxosmithkline updated related occurrence discontinuation syndrome including serious discontinuation acute overdosage often manifested emesis lethargy ataxia tachycardia seizures plasma serum blood concentrations paroxetine may measured monitor therapeutic administration confirm diagnosis poisoning hospitalized patients aid medicolegal investigation fatalities plasma paroxetine concentrations generally range μgl persons receiving daily therapeutic doses μgl poisoned patients postmortem blood levels ranged mgl acute lethal overdose along ssris sertraline fluoxetine paroxetine considered lowrisk drug cases interactions drugs acting serotonin system impairing metabolism serotonin may increase risk serotonin syndrome neuroleptic malignant syndrome nmslike reaction reactions observed snris ssris alone particularly concurrent use triptans mao inhibitors antipsychotics dopamine antagonists prescribing information states paroxetine used combination maoi including linezolid antibiotic reversible nonselective maoi within days discontinuing treatment maoi used combination pimozide thioridazine tryptophan paroxetine interacts following cytochrome paroxetine shown inhibitor g proteincoupled receptor kinase paroxetine potent one specific selective serotonin reuptake inhibitors also binds allosteric site serotonin transporter similarly escitalopram though less potently paroxetine also inhibits reuptake norepinephrine lesser extent based evidence four weeks administration rats equivalent mg paroxetine taken daily occupies approximately serotonin transporters prefrontal paroxetine wellabsorbed following oral absolute bioavailability evidence saturable first pass taken orally achieves maximum concentration reaches steadystate paroxetine exhibits significant interindividual variations volume distribution less oral dose excreted urine paroxetine mechanismbased inhibitor paroxetine approved medical use united states initially sold currently available generic commonly prescribed medication united states eleven million glaxosmithkline paid substantial fines paid settlements classaction lawsuits become subject several highly critical books marketing paroxetine particular offlabel marketing paroxetine children suppression negative research results relating use children allegations failed warn consumers substantial withdrawal effects associated use early gsk agreed settle charges consumer fraud legal discovery process also uncovered evidence deliberate systematic suppression unfavorable paxil research results one gsks internal documents read would commercially unacceptable include statement efficacy children demonstrated would undermine profile united states department justice fined glaxosmithkline billion withholding data unlawfully promoting use preparing article misleadingly reported effects paroxetine adolescents depression following clinical trial study february uk competition markets authority imposed record fines million companies found infringed european union uk competition law entering agreements delay market entry generic versions drug uk glaxosmithkline received bulk fines fined companies produce generics issued fines collectively total uk public health services likely claim damages overcharged period generic versions drug illegally blocked market generics less expensive glaxosmithkline may also face actions generics manufacturers incurred loss result anticompetitive april appeals lodged competition appeal tribunal companies gsk marketed paroxetine television advertisements throughout late early commercials also aired cr version drug beginning paroxetine ranked list bestselling drugs billion sales paroxetine fifthmost prescribed antidepressant us retail market million sales dropped slightly million paroxetine remained fifthmost prescribed antidepressant trade names include aropax paretin brisdelle deroxat pexeva paxtine paxetin paroxat sereupin daparox seroxat several studies suggested paroxetine used treatment premature ejaculation particular intravaginal ejaculation latency time ielt found increase somewhat longer delay achieved treatment ssris fluvoxamine fluoxetine sertraline however paroxetine taken acutely demand hours coitus resulted clinically irrelevant sexually unsatisfactory delay ejaculation inferior clomipramine induced fourfold also evidence paroxetine may effective treatment compulsive hot benefits paroxetine prescription diabetic chronic tension uncertain although evidence conflicting paroxetine may effective treatment dysthymia chronic disorder involving depressive symptoms days evidence support paroxetine selectively binds inhibits g proteincoupled receptor kinase mice heart failure since regulates activity beta adrenergic receptor becomes desensitized cases heart failure paroxetine paroxetine derivative could used heart failure treatment paroxetine identified potential diseasemodifying osteoarthritis paroxetine common finding waste highly toxic alga pseudokirchneriella subcapitata syn raphidocelis also toxic soil nematode caenorhabditis alberca et al finds paroxetine acts trypanocide alberca et al finds leishmanicide alberca finds paroxetine produces cell death promastigotes l mechanism action remains httpsenwikipediaorgwikiparoxetine